Skip to content

Clinical Study of Teriparatide before and after oral implant surgery to improve early osseointegration and bone loss after functional load in middle-aged and elderly patients with osteoporosis

Clinical Study of Teriparatide before and after oral implant surgery to improve early osseointegration and bone loss after functional load in middle-aged and elderly patients with osteoporosis

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000036741
Enrollment
Unknown
Registered
2020-08-25
Start date
2020-10-01
Completion date
Unknown
Last updated
2020-09-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dentition defect

Interventions

A:Basic treatment of osteoporosis (oral calcium tablets and vitamin D) was started 1 month before operation
B:Before implantation, teripaptide was given basic treatment for osteoporosis for 1 month
C:After the operation, only basic treatment of osteoporosis was given
D:After implantation, teripagin was given basic treatment for osteoporosis for 1 month

Sponsors

Ruijin Hospital, Affiliated to the School of Medicine, Shanghai Jiaotong University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) patients with clinically diagnosed dentition defect have more than one dentition defect and need dental implant. 2) the clinical diagnosis was osteoporosis, in accordance with the Teriparatide indications, good oral hygiene and good health; 3) the clinical examination: normal range of Keratinized Gingiva in the edentulous area, good color and mobility of the oral Mucosa. 4) x-ray or CT examination: the bone mass in the edentulous area of the jaw meets the conditions of dental implantation, and no bone graft is needed. 5) bone mineral density (BMD) was less than-2.5. 6) patients gave informed consent and were able to participate in multiple follow-up visits during the study period.

Exclusion criteria

Exclusion criteria: 1) implant patients requiring additional Bone Augmentation Surgery; 2) patients with a history of systemic diseases such as diabetes, cancer, radiation and chemotherapy, abnormal liver and kidney function, and heavy smoking. 3) patients who did not agree to participate in the study and who did not want to follow the study's blind method; 4) the researchers decided that other reasons were not appropriate for the clinical trial participants.

Design outcomes

Primary

MeasureTime frame
Implant stability;Implant looseness;Marginal bone level of implant;Peri-implant soft tissue level;

Secondary

MeasureTime frame
Bone density;Serological index;

Countries

China

Contacts

Public ContactJiang Liting

Ruijin Hospital, School of Medicine, Shanghai Jiaotong University

drjiangliting@163.com+86 3361981122

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026